CẬP NHẬT ĐIỀU TRỊ U MÔ ĐỆM ĐƯỜNG TIÊU HÓA (GISTs) GIAI ĐOẠN TÁI PHÁT DI CĂN

Abstract

This article aims to review and update the latest treatment issues in the treatment of gastrointestinal stromal tumors (GISTs) in the stage of metastatic recurrence or inoperability. In recent decades, the problem Diagnosis and treatment have made remarkable progress, allowing early and thorough diagnosis and treatment, bringing benefits in terms of survival time as well as improving the quality of life for patients. Thanks to the development of molecular biology, people have a better understanding of disease pathogenesis, especially the pathogenesis and molecular pathology characteristics of GISTs. It is the knowledge of molecular pathology that has contributed greatly to the diagnosis and treatment of GISTs [2]. Along with advances in medicine, the advent of the targeted drug Imatinib (Glivec) has created a revolution in the treatment of GISTs. The drug with the mechanism of selective inhibition of tyrosine kinases c-abl, bcr - abl, c - kit and PDGFR, interacts with this protein in the liver with ATP. Tumor cells will stop proliferating and enter the programmed death pathway (apoptosis).